3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Astrocytoma
8
Glioblastoma
5
Neuroectodermal Tumors, Primitive
3
Recurrence
2
Oligodendroglioma
2
Neurocytoma
2
Lymphoma, Non-Hodgkin
2
Glioma
2
Brain Neoplasms
2
Rhabdoid Tumor
1
Pancreatic Neoplasms
1
Neoplasms, Unknown Primary
1
Multiple Myeloma
1
Mesothelioma, Malignant
1
Meningioma
1
Melanoma
1
Lung Neoplasms
1
Gliosarcoma
1
Ganglioglioma
1
Esophageal Neoplasms
1
Ependymoma
1
Craniopharyngioma
1
Carcinoma, Non-Small-Cell Lung
1
Adrenocortical Carcinoma
1
Adenocarcinoma Of Esophagus
1
Interventions
Gemcitabine
47
Cisplatin
32
pembrolizumab
28
Paclitaxel
13
Docetaxel
13
avelumab
12
Mitomycin
12
atezolizumab
11
Nivolumab
11
Cystectomy
10
Carboplatin
9
durvalumab
7
Sunitinib
7
apaziquone
6
Doxorubicin
6
BCG Vaccine
6
5-aminolevulinic acid hexyl ester
6
Vinblastine
5
Radiation
5
Platinum
5
Methotrexate
5
Magnetic Resonance Spectroscopy
5
Albumin-Bound Paclitaxel
5
Taxes
4
Standard of Care
4
Sorafenib
4
Radiotherapy
4
Fluorouracil
4
Erlotinib Hydrochloride
4
1,2-diaminocyclohexaneplatinum II citrate
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Has results
×
Urinary Bladder Neoplasms
×
antineoplaston AS 2-1
×
Clear all
No trials found.